查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1765390

基因轉移系統的全球市場

Gene Delivery Systems
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球基因遞送系統市場規模將達到 62 億美元

全球基因遞送系統市場規模預計在2024年為43億美元，預計到2030年將達到62億美元，2024年至2030年的複合年成長率為6.5%。病毒基因是本報告分析的細分市場之一，預計其複合年成長率為6.9%，到分析期結束時規模將達到41億美元。非病毒基因細分市場在分析期間的複合年成長率估計為6.2%。

美國市場規模估計為 12 億美元，中國市場預期複合年成長率為 6.0%

美國基因遞送系統市場規模預計2024年達到12億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到9.674億美元，在2024-2030年的分析期間內，複合年成長率為6.0%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為5.8%和5.5%。在歐洲，預計德國市場的複合年成長率為4.9%。

全球基因傳遞系統市場－主要趨勢與促進因素摘要

什麼是基因轉殖系統？為什麼它們對現代醫學至關重要？

基因遞送系統是生物技術和醫學領域的重要工具，能夠將遺傳物質導入細胞，在分子層面上治療各種疾病。這些系統在基因治療、再生醫學和疫苗研發中發揮關鍵作用，可用於治療癌症、遺傳性疾病和感染疾病等疾病。病毒載體、脂質體和奈米顆粒是最常用的基因傳遞系統，它們各自在不同的應用領域中發揮獨特的優勢。個人化醫療領域的不斷發展進一步凸顯了這些系統的重要性，它們能夠根據個別患者的需求進行精準的基因介入。

科技創新如何推動基因轉殖？

基因遞送技術的進步正在徹底改變這些系統的功能和效率。非病毒遞送方法的創新，例如基於 CRISPR 的方法和電穿孔技術，正在提高基因治療的安全性和有效性。此外，能夠克服傳統限制（例如免疫系統活化和標靶能力有限）的合成載體的開發，正在拓展基因傳遞的潛在應用。奈米顆粒工程的進步使得遺傳物質的遞送和釋放更加精準，從而減少脫靶效應並改善患者預後。這些進步使基因遞送系統更加安全、有效，並適用於更廣泛的醫療應用。

為什麼基因治療解決方案的需求不斷增加？

基因治療解決方案因其有望為慢性和危及生命的疾病提供持久的治療方法，其需求正在飆升。隨著遺傳學和分子生物學研究的進步，越來越多的疾病可以透過基因治療得到治療，為此前被認為無法治癒的疾病開闢了新的治療途徑。罕見遺傳疾病、癌症和某些感染疾病是基因治療的主要目標，因此有效的基因傳遞系統對於成功至關重要。此外，個人化醫療的興起正在推動能夠進行特定和靶向基因修飾的遞送系統的發展，這與醫療行業根據個人基因圖譜客製化治療方法的目標相一致。

是什麼推動了基因傳遞系統市場的成長？

基因遞送系統市場的成長受到多種因素的推動，包括生物技術的進步、基因治療需求的不斷成長以及對個人化醫療日益成長的關注。 CRISPR 和合成載體等技術進步使得更有效率、更有針對性的基因傳遞方法成為可能，從而擴大了可治療疾病的範圍。隨著基因治療方案作為遺傳疾病和癌症的潛在治療方法日益受到關注，對有效遞送系統的需求也日益成長。此外，對精準醫療的日益重視也要求能夠針對個別患者進行特定、可控的基因介入的系統。這些因素共同作用，使基因遞送系統市場成為現代醫學的基石。

部分

遞送（病毒基因、非病毒基因、複雜雜交）、應用（腫瘤學、中樞神經系統、感染疾病、眼科、糖尿病、其他應用）

受訪公司範例

  • Amgen, Inc.
  • Bayer AG
  • Human Stem Cells Institute
  • Johnson & Johnson
  • Novartis AG
  • Oxford Biomedica plc
  • Pfizer, Inc.
  • Shanghai Sunway Biotech Co., Ltd.
  • Sibiono GeneTech Co. Ltd.

人工智慧整合

全球產業分析師正在利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global 特定產業SLM 的典型規範，而是建立了一個從全球專家收集的內容庫，其中包括視訊錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口狀況（成品和原始OEM）預測其競爭態勢的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括銷貨成本成本 (COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 競賽

簡介目錄
Product Code: MCP16418

Global Gene Delivery Systems Market to Reach US$6.2 Billion by 2030

The global market for Gene Delivery Systems estimated at US$4.3 Billion in the year 2024, is expected to reach US$6.2 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Viral Gene, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth in the Non-Viral Gene segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 6.0% CAGR

The Gene Delivery Systems market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$967.4 Million by the year 2030 trailing a CAGR of 6.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.8% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Gene Delivery Systems Market - Key Trends & Drivers Summarized

What Are Gene Delivery Systems and Why Are They Essential in Modern Medicine?

Gene delivery systems are vital tools in the field of biotechnology and medicine, enabling the introduction of genetic material into cells to treat various diseases at a molecular level. These systems play a crucial role in gene therapy, regenerative medicine, and vaccine development, addressing conditions like cancer, genetic disorders, and infectious diseases. Viral vectors, liposomes, and nanoparticles are among the most commonly used methods in gene delivery systems, each offering unique benefits for different applications. The growing field of personalized medicine further underscores the importance of these systems, as they enable precise genetic interventions tailored to individual patients’ needs.

How Is Technological Innovation Advancing Gene Delivery?

Technological advancements in gene delivery are revolutionizing the capabilities and efficiency of these systems. Innovations in non-viral delivery methods, such as CRISPR-based approaches and electroporation, are increasing the safety and efficacy of gene therapies. Additionally, the development of synthetic vectors that can overcome traditional limitations, such as immune system activation and limited targeting capabilities, is expanding the potential applications of gene delivery. Advances in nanoparticle engineering allow for more precise delivery and controlled release of genetic material, reducing off-target effects and improving patient outcomes. These advancements are making gene delivery systems safer, more effective, and suitable for a broader range of medical applications.

Why Is There Growing Demand for Gene Therapy Solutions?

The demand for gene therapy solutions is surging due to their potential to offer lasting cures for chronic and life-threatening conditions. As research in genetics and molecular biology progresses, more diseases are becoming treatable through gene therapy, opening new avenues for conditions previously considered incurable. Rare genetic disorders, cancers, and certain infectious diseases are prime targets for gene therapy, where effective gene delivery systems are essential to success. Additionally, with the rise in personalized medicine, there is a push for delivery systems that allow specific, targeted genetic modifications, aligning with the healthcare industry’s goal of creating treatments tailored to individual genetic profiles.

What Drives the Growth of the Gene Delivery Systems Market?

The growth in the gene delivery systems market is driven by several factors, including advancements in biotechnology, increasing demand for gene therapies, and the rising focus on personalized medicine. Technological progress, such as CRISPR and synthetic vector development, has enabled more efficient and targeted gene delivery methods, expanding the range of treatable diseases. The need for effective delivery systems is growing as gene therapy solutions gain traction as potential cures for genetic disorders and cancers. Furthermore, the emphasis on precision medicine is pushing for systems that allow for specific, controlled genetic interventions tailored to individual patients. Collectively, these factors are propelling the gene delivery systems market forward as it becomes a cornerstone in modern medicine.

SCOPE OF STUDY:

The report analyzes the Gene Delivery Systems market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Delivery (Viral Gene, Non-Viral Gene, Combined Hybrid); Application (Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 46 Featured) -

  • Amgen, Inc.
  • Bayer AG
  • Human Stem Cells Institute
  • Johnson & Johnson
  • Novartis AG
  • Oxford Biomedica plc
  • Pfizer, Inc.
  • Shanghai Sunway Biotech Co., Ltd.
  • Sibiono GeneTech Co. Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Tariff Impact on Global Supply Chain Patterns
    • Gene Delivery Systems - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Gene Therapy in Treating Genetic Disorders
    • Advancements in Viral and Non-Viral Gene Delivery Technologies
    • Increased Focus on Targeted and Precision Medicine for Enhanced Therapeutic Efficacy
    • Expansion of Gene Delivery Applications in Oncology and Rare Diseases
    • Growing Adoption of CRISPR and Other Gene Editing Tools for Gene Therapy
    • Surge in Research Funding for Developing Novel Gene Delivery Methods
    • Increased Demand for Safer and More Efficient Gene Delivery Vehicles
    • Development of Nanoparticle-Based Gene Delivery Systems for Better Bioavailability
    • Rising Investment in Gene Delivery for Regenerative Medicine and Cell Therapy
    • Expansion of Clinical Trials Investigating Gene Delivery for Neurological Disorders
    • Growth in Partnerships Between Biotech Firms and Academic Institutions
    • Focus on Improving Patient Outcomes and Reducing Side Effects in Gene Therapy
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Gene Delivery Systems Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Gene Delivery Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Gene Delivery Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Gene Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Viral Gene by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Non-Viral Gene by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Combined Hybrid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Combined Hybrid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Combined Hybrid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for CNS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for CNS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for CNS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Ophthalmology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Gene Delivery Systems by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Gene Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 101: Rest of World Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of World Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of World 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of World Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of World 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION